A potent and selective inhibitor targeting human and murine 12/15-LOX
Michelle Armstrong(University of California, Santa Cruz), Theodore R. Holman(University of California, Santa Cruz), Chakrapani Kalyanaraman(University of California, San Francisco), Anton Simeonov(National Institutes of Health), Ajit Jadhav(National Institutes of Health), Klaus van Leyen(Harvard University), Cody J. Freedman(University of California, Santa Cruz), David J. Maloney(National Institutes of Health), Matthew P. Jacobson(University of California, San Francisco), Joo Eun Jung(The University of Texas Health Science Center at Houston), Yi Zheng(Xuzhou University of Technology)
Cited by 18
Related Papers
Unexplored therapeutic opportunities in the human genome
|Nature Reviews Drug Discovery|2018|391
Erratum: Unexplored therapeutic opportunities in the human genome
|Nature Reviews Drug Discovery|2018|327
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance
|Cancer Cell|2018|255
Baicalein and 12/15-Lipoxygenase in the Ischemic Brain
|Stroke|2006|250
Cell–cell Signaling in the Neurovascular Unit
|Neurochemical Research|2007|238